Cancer Biomarkers Market Anticipated exceeding USD 74 Billion by 2035

Cancer Biomarkers Market Anticipated exceeding USD 74 Billion by 2035.

A comprehensive study exploring emerging opportunities in, “Cancer Biomarkers Market Size, Share, Growth Opportunity Analysis Report by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Glycoprotein Biomarkers, Epigenetic Biomarkers, Circulating Tumor DNA (ctDNA), Metabolic Biomarkers, Immune Biomarkers, Others), Profiling Technology, Cancer Type, Application, End Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A detailed study of the evolving market landscape in the Cancer Biomarkers industry highlights key growth drivers such as niche application leadership, technology-driven production and distribution, and shifting consumer preferences all of which underscore the Cancer Biomarkers industry’s strong potential to expand and scale globally.

Cancer Biomarkers Market Forecast 2035:

According to the report, the cancer biomarkers market is anticipated to grow from USD 26.8 Billion in 2025 to USD 74.3 Billion in 2035 at a CAGR of 9.7% during the forecast period. The cancer biomarker market is on a rapid growth path due to growing demand for more precise and early detection of cancer. Cancer biomarkers are biological components (proteins, genes, or DNA segments) that define whether someone has cancer, or is at risk for cancer. With oncology advancing toward more personalized treatment, cancer biomarkers give clinicians timely and meaningful information that help to determine what the best care is for the individual.

Many new blood and liquid biopsy biomarkers entered clinical practice in 2024 across North America, Europe, and Asia. Biomarker-based tests allow patients to avoid risks associated with needle biopsies, while providing real-time data about how effective a treatment is. Furthermore, digital pathology platforms are developing more ways to use AI to extract cancer biomarkers and analyze them in a timely fashion from lab samples - particularly in hospitals where the number of pathologists is limited.

Increased investment from governments and cancer foundations in biomarker-based national screening programs, and educational efforts are helping physicians and patients to understand that these tests can provide not just a diagnosis of cancer, but also predictions about treatment response and cancer recurrence. As cancer emerges as one of the world's top concerns related to our health, cancer biomarkers are instrumental in advancing oncology to be safer, faster, and more personalized.

“Key operators, limitations, and prospects for growth impacting the Cancer Biomarkers Market”

Roche Diagnostics, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, and Abbott Laboratories, are key participants in the cancer biomarkers market as they continue to invest in markers designed using genomic, proteomic, and liquid biopsy solutions. The dynamic offerings from these companies support genomics, proteomics and liquid biopsy incorporation of biomarkers into companion diagnostics and targeted therapies in lung, breast and colorectal cancers. The collective approach to innovation is enhanced through joint ventures with research institutes and pharmaceutical companies for further innovation in predictive and prognostic markers.

A significant hurdle in the cancer biomarkers market is the absence of standardization and reproducibility with testing platforms. Performance of a biomarker depends on many factors including sample type, testing technology and population genetics. Costly tests and limited reimbursement in some areas are also barriers to widespread clinical implementation. Likewise, the regulatory burden slows regulatory approval for new biomarker-based assays.

The cancer biomarkers market will continue to grow with considerable charitable contributions due to the shift from traditional oncology to precision oncology, early cancer detection, and the potential of liquid biopsy testing, AI-enabled biomarker analysis, and next-generation sequencing to provide less invasive and more informative tests. Furthermore, government funding, cancer screening programs and the inclusion of biomarkers in clinical guidelines for organizing their clinical use is a further support of their implementation. With healthcare systems focusing on individualized treatment approaches, cancer biomarkers will be pivotal in the future of oncology care.

"The Implications of Worldwide Tariff Regulations on the Cancer Biomarkers Market Industry Growth and Techniques"

Global tariffs can play a major role in impacting the cancer biomarkers market, mainly because much of the development and availability of advanced biomarkers rely on imports for advanced testing kits and reagents and sequencing machines. High tariffs on diagnostic tools or raw materials can increase the prices for labs and hospitals and, in turn, increase the costs borne to patients in many low- and middle-income countries as they can least afford the current costs already. Tariffs can also delay the uptake of cancer biomarker tests in low- and middle-income countries.

However, exemptions from tariffs on important diagnostic products - especially during public health campaigns - and broaden the availability of biomarkers in national screening and early diagnosis programs. In total, global tariffs impact the viability of smoother international trade in diagnostic tools and ultimately broaden access and enable more widespread personalized cancer care.

An upsurge in Cancer Biomarkers Market

“Accelerating Cancer Biomarkers Market Growth Backed by Early Detection Needs, Precision Medicine, and Technological Progress”

Due to increasing demand for early cancer detection and personalized treatment, the rapidly increasing cancer biomarkers market is trending in a positive direction. Markers, either genetic, protein or protein found in blood, can assist doctors in diagnosing cancer sooner, tracking therapy response, and determining the best therapy available for the individual. This is especially impervious to the evolution of cancer incidents around the world and the fact that precision medicine is becoming the standard of care globally.
Further, one particular trend in the biomarkers market is the emergence of liquid biopsies, which are blood tests that extract the cancer biomarkers from the blood stream; thus, a surgery or tissue sample is unnecessary to help define the cancer at an earlier stage. There is also an increased use of AI and machine learning tools to help analyze the large amounts of data describing biomarkers that were once tedious and often inaccurate.
Moreover, these centers are also benefiting from government and health organization funding for their biomarker-based screening and have been included in their clinical guidelines. Biomarkers are helping to track patient response to therapy and provide quicker accessibility to diagnostics, while facilitating targeted and individualized care as the most modern health systems are shifting to personalized and tailored therapies. Thus, at both the developed and emerging healthcare system levels, the cancer biomarkers market is only going to grow.

Regional Analysis of Cancer Biomarkers Market

North America is the highest growth segment for cancer biomarkers globally, with high cancer incidence, investment in research, and the early adoption of personalized medicine. The U.S. has today a plethora of biotechnology companies and academic centers engaged in biomarker innovations. In addition to overarching growth segment of cancer biomarkers, Europe has made significant advances as well, including the increasing utilization of biomarker tests in hospital systems and cancer screening programs.
Further, the Asia-Pacific region is growing the fastest when compared to North America and Europe and is driven primarily by increasing awareness of cancer, higher capacity of laboratories, as well as government initiatives to promote early cancer diagnosis. The only points of impediment in Asia-Pacific may be arising from high testing costs and the lack of trained personnel in certain nations.

Key players operating in the cancer biomarkers market include Abbott Laboratories, Agilent Technologies, Inc., Amgen Inc., AstraZeneca plc, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Guardant Health, Inc., Illumina, Inc., Merck & Co., Inc., Myriad Genetics, Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Other Key Players

The cancer biomarkers market has been segmented as follows:

Cancer Biomarkers Market Analysis, by Biomarker Type

Genetic Biomarkers
Protein Biomarkers
Glycoprotein Biomarkers
Epigenetic Biomarkers
Circulating Tumor DNA (ctDNA)
Metabolic Biomarkers
Immune Biomarkers
Others

Cancer Biomarkers Market Analysis, by Profiling Technology

Omics Technologies
Imaging Technologies
Immunoassays
Bioinformatics
Next-Generation Sequencing (NGS)
PCR (Polymerase Chain Reaction)
Microarrays
Flow Cytometry
Mass Spectrometry
Others

Cancer Biomarkers Market Analysis, by Cancer Type

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Ovarian Cancer
Melanoma
Blood Cancer
Liver Cancer
Pancreatic Cancer
Cervical Cancer
Brain Tumors
Stomach Cancer
Others

Cancer Biomarkers Market Analysis, by Application

Diagnostics
Prognostics
Risk Assessment
Drug Discovery & Development
Therapy Monitoring
Companion Diagnostics
Screening & Surveillance
Recurrence Monitoring
Clinical Trial Testing
Others

Cancer Biomarkers Market Analysis, by End-users

Hospitals & Clinics
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Diagnostic Laboratories
Contract Research Organizations (CROs)
Cancer Centers
Government Research Bodies
Others

Cancer Biomarkers Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Cancer Biomarkers Market Outlook
  - 2.1.1. Cancer Biomarkers Market Size (Value - US$ Billion), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2025-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Cancer Biomarkers Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Early Detection, Personalized Treatment, and Non-Invasive Testing Driving Growth in Cancer Biomarkers Market
  - 4.1.2. Restraints
    - 4.1.2.1. High Testing Costs, Regulatory Barriers, and Limited Standardization Slowing Biomarker Adoption
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
  - 4.4.1. Raw Material Sourcing
  - 4.4.2. Manufacturing and Processing
  - 4.4.3. Wholesalers/ E-commerce Platform
  - 4.4.4. End-use/ Customers
- 4.5. Cost Structure Analysis
  - 4.5.1. Parameter’s Share for Cost Associated
  - 4.5.2. COGP vs COGS
  - 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
  - 4.6.1. Regional Pricing Analysis
  - 4.6.2. Segmental Pricing Trends
  - 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Cancer Biomarkers Market Demand
  - 4.9.1. Historical Market Size - Value (US$ Billion), 2021-2024
  - 4.9.2. Current and Future Market Size - Value (US$ Billion), 2025–2035
    - 4.9.2.1. Y-o-Y Growth Trends
    - 4.9.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Cancer Biomarkers Market Analysis, by Biomarker Type
- 6.1. Key Segment Analysis
- 6.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by Biomarker Type, 2021-2035
  - 6.2.1. Genetic Biomarkers
  - 6.2.2. Protein Biomarkers
  - 6.2.3. Glycoprotein Biomarkers
  - 6.2.4. Epigenetic Biomarkers
  - 6.2.5. Circulating Tumor DNA (ctDNA)
  - 6.2.6. Metabolic Biomarkers
  - 6.2.7. Immune Biomarkers
  - 6.2.8. Others
7. Cancer Biomarkers Market Analysis, by Profiling Technology
- 7.1. Key Segment Analysis
- 7.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by Profiling Technology, 2021-2035
  - 7.2.1. Omics Technologies
  - 7.2.2. Imaging Technologies
  - 7.2.3. Immunoassays
  - 7.2.4. Bioinformatics
  - 7.2.5. Next-Generation Sequencing (NGS)
  - 7.2.6. PCR (Polymerase Chain Reaction)
  - 7.2.7. Microarrays
  - 7.2.8. Flow Cytometry
  - 7.2.9. Mass Spectrometry
  - 7.2.10. Others
8. Cancer Biomarkers Market Analysis, by Cancer Type
- 8.1. Key Segment Analysis
- 8.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by Cancer Type, 2021-2035
  - 8.2.1. Breast Cancer
  - 8.2.2. Lung Cancer
  - 8.2.3. Prostate Cancer
  - 8.2.4. Colorectal Cancer
  - 8.2.5. Ovarian Cancer
  - 8.2.6. Melanoma
  - 8.2.7. Blood Cancer
  - 8.2.8. Liver Cancer
  - 8.2.9. Pancreatic Cancer
  - 8.2.10. Cervical Cancer
  - 8.2.11. Brain Tumors
  - 8.2.12. Stomach Cancer
  - 8.2.13. Others
9. Cancer Biomarkers Market Analysis, by Application
- 9.1. Key Segment Analysis
- 9.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by Application, 2021-2035
  - 9.2.1. Diagnostics
  - 9.2.2. Prognostics
  - 9.2.3. Risk Assessment
  - 9.2.4. Drug Discovery & Development
  - 9.2.5. Therapy Monitoring
  - 9.2.6. Companion Diagnostics
  - 9.2.7. Screening & Surveillance
  - 9.2.8. Recurrence Monitoring
  - 9.2.9. Clinical Trial Testing
  - 9.2.10. Others
10. Cancer Biomarkers Market Analysis, by End-users
- 10.1. Key Segment Analysis
- 10.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by End-users, 2021-2035
  - 10.2.1. Hospitals & Clinics
  - 10.2.2. Academic & Research Institutes
  - 10.2.3. Pharmaceutical & Biotechnology Companies
  - 10.2.4. Diagnostic Laboratories
  - 10.2.5. Contract Research Organizations (CROs)
  - 10.2.6. Cancer Centers
  - 10.2.7. Government Research Bodies
  - 10.2.8. Others
11. Cancer Biomarkers Market Analysis and Forecasts, by Region
- 11.1. Key Findings
- 11.2. Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
  - 11.2.1. North America
  - 11.2.2. Europe
  - 11.2.3. Asia Pacific
  - 11.2.4. Middle East
  - 11.2.5. Africa
  - 11.2.6. South America
12. North America Cancer Biomarkers Market Analysis
- 12.1. Key Segment Analysis
- 12.2. Regional Snapshot
- 12.3. North America Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 12.3.1. Biomarker Type
  - 12.3.2. Profiling Technology
  - 12.3.3. Cancer Type
  - 12.3.4. Application
  - 12.3.5. End-users
  - 12.3.6. Country
    - 12.3.6.1. USA
    - 12.3.6.2. Canada
    - 12.3.6.3. Mexico
- 12.4. USA Cancer Biomarkers Market
  - 12.4.1. Country Segmental Analysis
  - 12.4.2. Biomarker Type
  - 12.4.3. Profiling Technology
  - 12.4.4. Cancer Type
  - 12.4.5. Application
  - 12.4.6. End-users
- 12.5. Canada Cancer Biomarkers Market
  - 12.5.1. Country Segmental Analysis
  - 12.5.2. Biomarker Type
  - 12.5.3. Profiling Technology
  - 12.5.4. Cancer Type
  - 12.5.5. Application
  - 12.5.6. End-users
- 12.6. Mexico Cancer Biomarkers Market
  - 12.6.1. Country Segmental Analysis
  - 12.6.2. Biomarker Type
  - 12.6.3. Profiling Technology
  - 12.6.4. Cancer Type
  - 12.6.5. Application
  - 12.6.6. End-users
13. Europe Cancer Biomarkers Market Analysis
- 13.1. Key Segment Analysis
- 13.2. Regional Snapshot
- 13.3. Europe Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 13.3.1. Biomarker Type
  - 13.3.2. Profiling Technology
  - 13.3.3. Cancer Type
  - 13.3.4. Application
  - 13.3.5. End-users
  - 13.3.6. Country
    - 13.3.6.1. Germany
    - 13.3.6.2. United Kingdom
    - 13.3.6.3. France
    - 13.3.6.4. Italy
    - 13.3.6.5. Spain
    - 13.3.6.6. Netherlands
    - 13.3.6.7. Nordic Countries
    - 13.3.6.8. Poland
    - 13.3.6.9. Russia & CIS
    - 13.3.6.10. Rest of Europe
- 13.4. Germany Cancer Biomarkers Market
  - 13.4.1. Country Segmental Analysis
  - 13.4.2. Biomarker Type
  - 13.4.3. Profiling Technology
  - 13.4.4. Cancer Type
  - 13.4.5. Application
  - 13.4.6. End-users
- 13.5. United Kingdom Cancer Biomarkers Market
  - 13.5.1. Country Segmental Analysis
  - 13.5.2. Biomarker Type
  - 13.5.3. Profiling Technology
  - 13.5.4. Cancer Type
  - 13.5.5. Application
  - 13.5.6. End-users
- 13.6. France Cancer Biomarkers Market
  - 13.6.1. Country Segmental Analysis
  - 13.6.2. Biomarker Type
  - 13.6.3. Profiling Technology
  - 13.6.4. Cancer Type
  - 13.6.5. Application
  - 13.6.6. End-users
- 13.7. Italy Cancer Biomarkers Market
  - 13.7.1. Country Segmental Analysis
  - 13.7.2. Biomarker Type
  - 13.7.3. Profiling Technology
  - 13.7.4. Cancer Type
  - 13.7.5. Application
  - 13.7.6. End-users
- 13.8. Spain Cancer Biomarkers Market
  - 13.8.1. Country Segmental Analysis
  - 13.8.2. Biomarker Type
  - 13.8.3. Profiling Technology
  - 13.8.4. Cancer Type
  - 13.8.5. Application
  - 13.8.6. End-users
- 13.9. Netherlands Cancer Biomarkers Market
  - 13.9.1. Country Segmental Analysis
  - 13.9.2. Biomarker Type
  - 13.9.3. Profiling Technology
  - 13.9.4. Cancer Type
  - 13.9.5. Application
  - 13.9.6. End-users
- 13.10. Nordic Countries Cancer Biomarkers Market
  - 13.10.1. Country Segmental Analysis
  - 13.10.2. Biomarker Type
  - 13.10.3. Profiling Technology
  - 13.10.4. Cancer Type
  - 13.10.5. Application
  - 13.10.6. End-users
- 13.11. Poland Cancer Biomarkers Market
  - 13.11.1. Country Segmental Analysis
  - 13.11.2. Biomarker Type
  - 13.11.3. Profiling Technology
  - 13.11.4. Cancer Type
  - 13.11.5. Application
  - 13.11.6. End-users
- 13.12. Russia & CIS Cancer Biomarkers Market
  - 13.12.1. Country Segmental Analysis
  - 13.12.2. Biomarker Type
  - 13.12.3. Profiling Technology
  - 13.12.4. Cancer Type
  - 13.12.5. Application
  - 13.12.6. End-users
- 13.13. Rest of Europe Cancer Biomarkers Market
  - 13.13.1. Country Segmental Analysis
  - 13.13.2. Biomarker Type
  - 13.13.3. Profiling Technology
  - 13.13.4. Cancer Type
  - 13.13.5. Application
  - 13.13.6. End-users
14. Asia Pacific Cancer Biomarkers Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. East Asia Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Biomarker Type
  - 14.3.2. Profiling Technology
  - 14.3.3. Cancer Type
  - 14.3.4. Application
  - 14.3.5. End-users
  - 14.3.6. Country
    - 14.3.6.1. China
    - 14.3.6.2. India
    - 14.3.6.3. Japan
    - 14.3.6.4. South Korea
    - 14.3.6.5. Australia and New Zealand
    - 14.3.6.6. Indonesia
    - 14.3.6.7. Malaysia
    - 14.3.6.8. Thailand
    - 14.3.6.9. Vietnam
    - 14.3.6.10. Rest of Asia-Pacific
- 14.4. China Cancer Biomarkers Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Biomarker Type
  - 14.4.3. Profiling Technology
  - 14.4.4. Cancer Type
  - 14.4.5. Application
  - 14.4.6. End-users
- 14.5. India Cancer Biomarkers Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Biomarker Type
  - 14.5.3. Profiling Technology
  - 14.5.4. Cancer Type
  - 14.5.5. Application
  - 14.5.6. End-users
- 14.6. Japan Cancer Biomarkers Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Biomarker Type
  - 14.6.3. Profiling Technology
  - 14.6.4. Cancer Type
  - 14.6.5. Application
  - 14.6.6. End-users
- 14.7. South Korea Cancer Biomarkers Market
  - 14.7.1. Country Segmental Analysis
  - 14.7.2. Biomarker Type
  - 14.7.3. Profiling Technology
  - 14.7.4. Cancer Type
  - 14.7.5. Application
  - 14.7.6. End-users
- 14.8. Australia and New Zealand Cancer Biomarkers Market
  - 14.8.1. Country Segmental Analysis
  - 14.8.2. Biomarker Type
  - 14.8.3. Profiling Technology
  - 14.8.4. Cancer Type
  - 14.8.5. Application
  - 14.8.6. End-users
- 14.9. Indonesia Cancer Biomarkers Market
  - 14.9.1. Country Segmental Analysis
  - 14.9.2. Biomarker Type
  - 14.9.3. Profiling Technology
  - 14.9.4. Cancer Type
  - 14.9.5. Application
  - 14.9.6. End-users
- 14.10. Malaysia Cancer Biomarkers Market
  - 14.10.1. Country Segmental Analysis
  - 14.10.2. Biomarker Type
  - 14.10.3. Profiling Technology
  - 14.10.4. Cancer Type
  - 14.10.5. Application
  - 14.10.6. End-users
- 14.11. Thailand Cancer Biomarkers Market
  - 14.11.1. Country Segmental Analysis
  - 14.11.2. Biomarker Type
  - 14.11.3. Profiling Technology
  - 14.11.4. Cancer Type
  - 14.11.5. Application
  - 14.11.6. End-users
- 14.12. Vietnam Cancer Biomarkers Market
  - 14.12.1. Country Segmental Analysis
  - 14.12.2. Biomarker Type
  - 14.12.3. Profiling Technology
  - 14.12.4. Cancer Type
  - 14.12.5. Application
  - 14.12.6. End-users
- 14.13. Rest of Asia Pacific Cancer Biomarkers Market
  - 14.13.1. Country Segmental Analysis
  - 14.13.2. Biomarker Type
  - 14.13.3. Profiling Technology
  - 14.13.4. Cancer Type
  - 14.13.5. Application
  - 14.13.6. End-users
15. Middle East Cancer Biomarkers Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Middle East Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Biomarker Type
  - 15.3.2. Profiling Technology
  - 15.3.3. Cancer Type
  - 15.3.4. Application
  - 15.3.5. End-users
  - 15.3.6. Country
    - 15.3.6.1. Turkey
    - 15.3.6.2. UAE
    - 15.3.6.3. Saudi Arabia
    - 15.3.6.4. Israel
    - 15.3.6.5. Rest of Middle East
- 15.4. Turkey Cancer Biomarkers Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Biomarker Type
  - 15.4.3. Profiling Technology
  - 15.4.4. Cancer Type
  - 15.4.5. Application
  - 15.4.6. End-users
- 15.5. UAE Cancer Biomarkers Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Biomarker Type
  - 15.5.3. Profiling Technology
  - 15.5.4. Cancer Type
  - 15.5.5. Application
  - 15.5.6. End-users
- 15.6. Saudi Arabia Cancer Biomarkers Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Biomarker Type
  - 15.6.3. Profiling Technology
  - 15.6.4. Cancer Type
  - 15.6.5. Application
  - 15.6.6. End-users
- 15.7. Israel Cancer Biomarkers Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Biomarker Type
  - 15.7.3. Profiling Technology
  - 15.7.4. Cancer Type
  - 15.7.5. Application
  - 15.7.6. End-users
- 15.8. Rest of Middle East Cancer Biomarkers Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Biomarker Type
  - 15.8.3. Profiling Technology
  - 15.8.4. Cancer Type
  - 15.8.5. Application
  - 15.8.6. End-users
16. Africa Cancer Biomarkers Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Africa Cancer Biomarkers Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Biomarker Type
  - 16.3.2. Profiling Technology
  - 16.3.3. Cancer Type
  - 16.3.4. Application
  - 16.3.5. End-users
  - 16.3.6. Country
    - 16.3.6.1. South Africa
    - 16.3.6.2. Egypt
    - 16.3.6.3. Nigeria
    - 16.3.6.4. Algeria
    - 16.3.6.5. Rest of Africa
- 16.4. South Africa Cancer Biomarkers Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Biomarker Type
  - 16.4.3. Profiling Technology
  - 16.4.4. Cancer Type
  - 16.4.5. Application
  - 16.4.6. End-users
- 16.5. Egypt Cancer Biomarkers Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Biomarker Type
  - 16.5.3. Profiling Technology
  - 16.5.4. Cancer Type
  - 16.5.5. Application
  - 16.5.6. End-users
- 16.6. Nigeria Cancer Biomarkers Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Biomarker Type
  - 16.6.3. Profiling Technology
  - 16.6.4. Cancer Type
  - 16.6.5. Application
  - 16.6.6. End-users
- 16.7. Algeria Cancer Biomarkers Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Biomarker Type
  - 16.7.3. Profiling Technology
  - 16.7.4. Cancer Type
  - 16.7.5. Application
  - 16.7.6. End-users
- 16.8. Rest of Africa Cancer Biomarkers Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Biomarker Type
  - 16.8.3. Profiling Technology
  - 16.8.4. Cancer Type
  - 16.8.5. Application
  - 16.8.6. End-users
17. South America Cancer Biomarkers Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Central and South Africa Cancer Biomarkers Market Size ( Value - US$ Billion), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Biomarker Type
  - 17.3.2. Profiling Technology
  - 17.3.3. Cancer Type
  - 17.3.4. Application
  - 17.3.5. End-users
  - 17.3.6. Country
    - 17.3.6.1. Brazil
    - 17.3.6.2. Argentina
    - 17.3.6.3. Rest of South America
- 17.4. Brazil Cancer Biomarkers Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Biomarker Type
  - 17.4.3. Profiling Technology
  - 17.4.4. Cancer Type
  - 17.4.5. Application
  - 17.4.6. End-users
- 17.5. Argentina Cancer Biomarkers Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Biomarker Type
  - 17.5.3. Profiling Technology
  - 17.5.4. Cancer Type
  - 17.5.5. Application
  - 17.5.6. End-users
- 17.6. Rest of South America Cancer Biomarkers Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Biomarker Type
  - 17.6.3. Profiling Technology
  - 17.6.4. Cancer Type
  - 17.6.5. Application
  - 17.6.6. End-users
18. Key Players/ Company Profile
- 18.1. Abbott Laboratories
  - 18.1.1. Company Details/ Overview
  - 18.1.2. Company Financials
  - 18.1.3. Key Customers and Competitors
  - 18.1.4. Business/ Industry Portfolio
  - 18.1.5. Product Portfolio/ Specification Details
  - 18.1.6. Pricing Data
  - 18.1.7. Strategic Overview
  - 18.1.8. Recent Developments
- 18.2. Agilent Technologies, Inc.
- 18.3. Amgen Inc.
- 18.4. AstraZeneca plc
- 18.5. Becton, Dickinson and Company (BD)
- 18.6. Bio-Rad Laboratories, Inc.
- 18.7. Bristol-Myers Squibb Company
- 18.8. Eurofins Scientific SE
- 18.9. Exact Sciences Corporation
- 18.10. F. Hoffmann-La Roche Ltd.
- 18.11. GE Healthcare
- 18.12. Guardant Health, Inc.
- 18.13. Illumina, Inc.
- 18.14. Merck & Co., Inc.
- 18.15. Myriad Genetics, Inc.
- 18.16. PerkinElmer Inc.
- 18.17. QIAGEN N.V.
- 18.18. Siemens Healthineers AG
- 18.19. Sysmex Corporation
- 18.20. Thermo Fisher Scientific Inc.
- 18.21. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150.00

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950.00

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750.00

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation